Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Robinson

Showing results (81-90 of 167) with videos related to

Pageof 17
Sort By:
Thyroid : Official Journal of the American Thyroid Association|July 1, 2017
Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT TrialNaomi Kiyota, Bruce Robinson, Manisha Shah, et al.
Nephrology (Carlton, Vic.)|July 27, 2021
Physical functioning in patients with chronic kidney disease stage G3b-5 in Japan: The reach-J CKD cohort studyReiko Okubo, Masahide Kondo, Ryoya Tsunoda, et al.
ANZ Journal of Surgery|February 3, 2019
Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learntGrace T Y Kwok, Jing-Ting Zhao, Anthony R Glover, et al.
Molecular & Cellular Proteomics : MCP|February 8, 2025
Multiple Classes of Antigen Contribute to the Antigenic Landscape of MesotheliomaKirti Pandey, Pouya Faridi, Rochelle Ayala, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
Cancer Science|October 2, 2015
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerNaomi Kiyota, Martin Schlumberger, Kei Muro, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 1, 2019
Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)Maria Fusaro, Graziella D'Arrigo, Annalisa Pitino, et al.
Pageof 17

Showing results (81-90 of 167) with videos related to

Sort By:
Pageof 17
Thyroid : Official Journal of the American Thyroid Association|July 1, 2017
Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT TrialNaomi Kiyota, Bruce Robinson, Manisha Shah, et al.
Nephrology (Carlton, Vic.)|July 27, 2021
Physical functioning in patients with chronic kidney disease stage G3b-5 in Japan: The reach-J CKD cohort studyReiko Okubo, Masahide Kondo, Ryoya Tsunoda, et al.
ANZ Journal of Surgery|February 3, 2019
Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learntGrace T Y Kwok, Jing-Ting Zhao, Anthony R Glover, et al.
Molecular & Cellular Proteomics : MCP|February 8, 2025
Multiple Classes of Antigen Contribute to the Antigenic Landscape of MesotheliomaKirti Pandey, Pouya Faridi, Rochelle Ayala, et al.
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
Cancer Science|October 2, 2015
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerNaomi Kiyota, Martin Schlumberger, Kei Muro, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 1, 2019
Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)Maria Fusaro, Graziella D'Arrigo, Annalisa Pitino, et al.
Pageof 17